Top Banner
Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE (eg. Chymase in heart) End opeptidase Angiotensin 1-7 Releases ADH; ↑ PG; Natriuretic; ↓ RVR; ↓ BP (brain stem inj.) ? Role in effects of AC 1 2 3 7 8 9 1 NH2-Asp-Arg-Val…Pro-Phe-COOH 1 2 3 7 8 9 1 NH2-Asp-Arg-Val…Pro-Phe-COOH 1 2 3 7 8 NH2-Arg-Val…Pro-Phe-COOH 2 3 7 8 NH2-Asp-Arg-Val…Pro-Phe-Hist-Leu…COO + Renal Perfusion sure Na at Macula a cells Sympathetic e activity (ß-1) ±PG The Renin-Angiotensin System
21

Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Jan 03, 2016

Download

Documents

Donald Kelly
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Angiotensinogen

Angiotensin I

Angiotensin II

Angiotensin III

Renin

ACE

Aminopeptidase

Non-ACE(eg. Chymase

in heart)

Endopeptidase

Angiotensin 1-7Releases ADH; ↑ PG;Natriuretic; ↓ RVR; ↓ BP (brain stem inj.)? Role in effects of ACEI

1 2 3 7 8 9 10

NH2-Asp-Arg-Val…Pro-Phe-COOH1 2 3 7 8 9 10

NH2-Asp-Arg-Val…Pro-Phe-COOH1 2 3 7 8

NH2-Arg-Val…Pro-Phe-COOH 2 3 7 8

NH2-Asp-Arg-Val…Pro-Phe-Hist-Leu…COOH

+

1. ↓ Renal PerfusionPressure2. ↓ Na at Macula Densa cells3. ↑ Sympathetic nerve activity (ß-1)

±PG

The Renin-Angiotensin System

Page 2: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Angiotensin II

Vasoconstriction

AldosteroneSecretion

Direct RenalSodium Retention

↑ Thirst

ADH Release

↑ Cardiac Contractility

Sympathetic Facilitation:CentralNerve terminal(ganglionic ?)

Cardiac & Vascular Hypertrophy

All known physiologic effects are mediated by the angiotensin II type 1 receptor

ANGIOTENSIN II - SUPPORT OF THE BLOOD PRESSURE

Page 3: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Angiotensin Converting Enzyme Inhibitors

Large number of drugs available differ mainly in the following:

1. Potency2. Route of elimination3. Duration of action4. Being prodrugs or active drugs Similar therapeutic indications, adverse

effects and contraindications

Page 4: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Adverse Effects

• Hypotension• Renal Insufficiency (if bilateral renal artery

stenosis)• Hyperkalemia – special group of patients (Na

restricted, on K-sparing diuretic, COX inhibitors)• Cough (20 %)• Angioedema• With captopril especially: neutropenia, nephrotic

syndrome, skin rash, taste disturbances (SH group- related).

Kinin-related (?)

Page 5: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Binds to active site

Binds to Zn ion

Binds more stronglyto Zn – more active

Enalapril Lisinopril

Page 6: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.
Page 7: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors and Left Ventricular Hypertrophy

Page 8: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors and Left Ventricular Hypertrophy

Page 9: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors after Myocardial Infarction

Page 10: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors in Heart Failure

Study of LV Dysfunction (SOLVD)

Page 11: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Survival and Ventricular Enlargement Trial (SAVE)Asymptomatic Patients with EF<40% ACE Inhibitors in Severe Heart Failure

Patients with Severe Heart FailureCooperative New Scandinavian Enalapril Survival Study (CONSENSUS)

Captopril

Placebo

Mor

tali

ty R

ate

Pro

bab

ilit

y of

Su

dd

en D

eath

Pro

bab

ilit

y of

Su

rviv

al

Captopril

Hydralazine

Enalapril

Placebo

Page 12: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors – Effect onProgression of Diabetic

Nephropathy

Enalapril

Enalapril

Metoprolol

Metoprolol

Page 13: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitors – Effect onProgression of Non-Diabetic

Nephropathy

Page 14: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Therapeutic Uses

• Anti-hypertensive• Prevent or reverse LVH• Protect against sudden death and second

myocardial infarction after acute MI• Improve survival and hemodynamics in

patients with congestive heart failure• Protect against progression of diabetic and

non-diabetic nephropathy

Page 15: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Losartan

Valsartan

Candesartan

Angiotensin II Type 1 Receptor Blockers

Page 16: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Angiotensin Receptor Blockers e.g. Losartan

• Block only the AT-1 subtype• Comparable effects to ACE Inhibitors in almost

all situations.• Less decrease in GFR in volume depleted states• Less side effects especially cough, angioedema,

rash• Block all AII effects and not dependent on

particular pathway

Kinins(?)

Page 17: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

P E LP LC

P: PlaceboE: EnalaprilL: LosartanC: Captopril

3 m

onth

mor

tali

ty (

%)

SOLVD US +Int’lExercise

ELITE

(n=2569) (n=722)(n=736)

Fig. 3: 3-month mortality in three different studies

ELITE STUDY GROUP (Evaluation of Losartan in the Elderly) – Losartan better than captopril in patients with heart failure (chance finding?)

Page 18: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Captopril

Losartan

ELITE STUDY GROUP Losartan Superior to Captopril (? Chance Finding)

Pro

bab

ility

of

Su

rviv

al

Follow-up (days)

Page 19: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ELITE II STUDY GROUP (3,152 patients for 1.5 y)No Difference between Captopril and Losartan

ProbabilityOf Survival %

Event-freeProbability %

Lancet. 2000;355:1582-7.

Page 20: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

Hypertensive Patients with Nephropathy

Page 21: Angiotensinogen Angiotensin I Angiotensin II Angiotensin III Renin ACE Aminopeptidase Non-ACE ( eg. Chymase in heart ) Endopeptidase Angiotensin 1-7 Releases.

ACE Inhibitor AII Receptor Blocker

Blocks formationof AII incompletely

Blocks Kininase II

↑ Kinins↓ AII effects & aldosterone

PROTECTION

Blocks AT-1R

AT-2R Free

More completeInhibition of AII effects

Preserve Anti-proliferativeeffect